
Feature|Articles|June 27, 2025
Biden’s prostate cancer diagnosis underscores importance of screening, awareness
Author(s)Hannah Clarke
Fact checked by: Benjamin P. Saylor, Strategic Content Lead
The unfortunate news of President Biden’s diagnosis has put a spotlight on prostate cancer, offering an opportunity to educate on the risks of the disease and the benefits of screening.
Advertisement
Advertisement
Former President Joseph R. Biden’s recent diagnosis of grade group 5 de novo metastatic hormone-sensitive prostate cancer has offered a sobering reminder that prostate cancer remains a growing concern for public health. In the US, incidence rates have been steadily rising since 2014, driven primarily by increases in advanced disease. The American Cancer Society (ACS) estimates that in 2025, more than 313,000 men will be diagnosed with prostate cancer and over 35,000 men will die from the disease.1
Related to this article

Jack R. Andrews, MD, discusses BED-PSMA-411 findings comparing PSMA-PET detection rates and urinary excretion in prostate cancer biochemical recurrence.

VIR-5500 is a PSMA-targeted PRO-XTEN dual-masked T-cell engager entering phase 3 development for prostate cancer.

Abraham Morgentaler, MD, reviews evidence showing no association between testosterone therapy and prostate cancer risk and explains the saturation model of androgen action.

Based on these results, the trial protocol has been amended to move enrollment earlier in the course of disease progression.

An analysis of NRG/RTOG 0815 found Decipher predicted distant metastasis risk and identified patients with greater benefit from short-term ADT.

Exploratory analyses suggest persistent immune remodeling after aglatimagene plus radiation in localized prostate cancer.

Brian Mazzarella, MD, discusses the landscape for intermediate-risk prostate cancer and early VAPOR 2 findings on water vapor ablation.
Advertisement
Advertisement
